Evidence map›Paper›PMID 30469444›Full record

ReviewVaccines2018

Fast Tracks and Roadblocks for Zika Vaccines.

Khairunnisa Abdul Ghaffar, Lisa F P Ng, Laurent Renia

Abstract readReview
In one paragraph

Review in Vaccines, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Pre-Clinical Pregnancy Models for Evaluating Zika Vaccines.Tropical medicine and infectious disease · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Khairunnisa Abdul GhaffarSingapore Immunology Network, Agency for Science, Technology and Research (A*STAR), Singapore 138648, Singapore. khairunnisa_ghaffar@immunol.a-star.edu.sg.
Lisa F P NgSingapore Immunology Network, Agency for Science, Technology and Research (A*STAR), Singapore 138648, Singapore. lisa_ng@immunol.a-star.edu.sg.
Laurent ReniaSingapore Immunology Network, Agency for Science, Technology and Research (A*STAR), Singapore 138648, Singapore. renia_laurent@immunol.a-star.edu.sg.ORCID 0000-0003-0349-1557

Funding

Agency for Science, Technology and Research Core fundBMRC A*STAR-led Zika Virus Consortium Fund 15/1/82/27/001
6 · The paper itself

Abstract

In early 2014, a relatively obscure virus, the Zika virus, made headlines worldwide following an increase in the number of congenital malformations. Since then, research on Zika virus, treatment and vaccines have progressed swiftly with various drugs being repurposed and vaccines heading into clinical trials. Nonetheless, the need for a vaccine is crucial in order to eradicate this re-emerging arthropod-borne virus which remained silent since its first discovery in 1947. In this review, we focused on how the inconspicuous virus managed to spread, the key immunological factors required for a vaccine and the various vaccine platforms that are currently being studied.

Indexed as

delivery systemsimmune responsesvaccineZika virus

Identifiers

PMID30469444
PMCPMC6313897

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.